A5014970964- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Silicon Carbide Semiconductor Technologies
- Phagocytosis and Immune Regulation
- Advancements in Semiconductor Devices and Circuit Design
- Virus-based gene therapy research
- Peptidase Inhibition and Analysis
- Immunotherapy and Immune Responses
- Macrophage Migration Inhibitory Factor
- Integrated Circuits and Semiconductor Failure Analysis
- Cancer-related gene regulation
- Toxin Mechanisms and Immunotoxins
- Hidradenitis Suppurativa and Treatments
MorphoSys (Germany)
2021-2024
In the development of various strategies anti-CD19 immunotherapy for treatment B-cell malignancies, it remains unclear whether CD19 monoclonal antibody therapy impairs subsequent CD19-targeted chimeric antigen receptor T-cell (CART19) therapy. We evaluated potential interference between CD19-targeting tafasitamab and CART19 in preclinical models. Concomitant with showed major binding competition, which led to functional impairment. However, when CD19+ cell lines were pretreated overnight...
Macrophages are one of the key mediators therapeutic effects exerted by monoclonal antibodies, such as anti-CD19 antibody tafasitamab, approved in combination with lenalidomide for treatment relapsed or refractory (r/r) diffuse large B cell lymphoma (DLBCL). However, antibody-dependent cellular phagocytosis (ADCP) tumor microenvironment can be counteracted increased expression inhibitory receptor SIRPα on macrophages and its ligand, immune checkpoint molecule CD47 cells. The aim this study...
Tafasitamab is an Fc-modified monoclonal antibody that binds to CD19, a cell-surface antigen broadly expressed on various types of B-cell non-Hodgkin's lymphoma (NHL). Antibody-dependent cellular cytotoxicity (ADCC), key mode action tafasitamab, mediated through the binding tafasitamab's Fc region FcγRIIIa receptors immune effector cells and results in antitumor activity. Despite proven clinical activity tafasitamab combination with lenalidomide treatment diffuse large (DLBCL), higher number...
Despite recent advances in the treatment of aggressive lymphomas, a significant fraction patients still succumbs to their disease. Thus, novel therapies are urgently needed. As anti-CD20 antibody rituximab and CD19-targeting tafasitamab share distinct modes actions, we investigated if dual-targeting lymphoma B-cells by combining might increase cytotoxic effects.Antibody single combination efficacy was determined investigating different action including direct cytotoxicity, antibody-dependent...
Introduction Several CD19 targeted antibody-based therapeutics are currently available for patients with diffuse large B-cell lymphoma (DLBCL), including the Fc-modified antibody immunotherapy tafasitamab. This therapeutic landscape warrants evaluation of potential sequencing approaches. Prior to a subsequent CD19-targeted therapy, expression on tafasitamab-treated patient biopsy samples may be assessed. However, no standardized methods its detection available. In this context, selecting...
Hidradenitis suppurativa (HS) is a chronic debilitating inflammatory skin disorder known to result in significant psychological symptoms and impaired quality of life. However, most these studies are limited western countries, with data from other sociocultural regions.To understand the psychosocial burden HS Asian context, by exploring correlation between objective disease measures health work productivity.A prospective single-center questionnaire study was conducted. A total 45 patients...
Topic: 20. Lymphoma Biology & Translational Research Background: Tafasitamab (tafa), an anti-CD19 immunotherapy that enhances antibody dependent cellular cytotoxicity (ADCC) and phagocytosis, achieved a 57.5% objective response rate in combination with lenalidomide the phase 2 L-MIND trial (NCT02399085), received accelerated US approval conditional authorization Europe for treatment of patients relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ineligible autologous stem cell...